Orgenesis Inc. (NASDAQ:ORGS – Get Free Report) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 33,800 shares, a drop of 40.0% from the September 30th total of 56,300 shares. Based on an average daily volume of 41,400 shares, the short-interest ratio is currently 0.8 days. Approximately 0.3% of the company’s shares are short sold.
Orgenesis Trading Up 0.8 %
NASDAQ ORGS opened at $1.20 on Friday. Orgenesis has a fifty-two week low of $1.03 and a fifty-two week high of $10.80.
Orgenesis (NASDAQ:ORGS – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($2.30) earnings per share for the quarter. The business had revenue of $0.25 million for the quarter.
Orgenesis Company Profile
Orgenesis Inc, a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.
Read More
- Five stocks we like better than Orgenesis
- Pros And Cons Of Monthly Dividend Stocks
- Texas Roadhouse Stock Steering for New Highs This Year
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
